Adimab
Is this your brand? Claim it — free, and takes a minute with your work email.
Overview
Tagline Brand's website · 2026-10-04
Premier yeast-based antibody discovery platform combining fully human synthetic and immune libraries, built on developability, with an integrated process from target to preclinical lead. It boasts a proven track record of over 140 biopharma partnerships and no internal pipeline, ensuring full alignment with partners' goals.
Description Brand's website · 2026-10-04
Adimab is a therapeutic antibody discovery and protein engineering platform that partners with biopharma companies to advance therapeutic proteins from concept to clinic. They offer a full suite of solutions including IgGs, HCAbs, multispecifics, and TCRs, leveraging a proprietary yeast-based platform for high specificity, stability, and developability.
Offerings
Core capabilities Brand's website · 2026-10-04
- Proprietary yeast-based antibody discovery platform; therapeutic antibody discovery and protein engineering services; capabilities for IgGs
- HCAbs
- multispecifics
- and TCRs; specific solutions for antibody discovery
- antibody engineering
- multispecific antibodies and T cell engagers
- and protein and TCR engineering.
Pricing Brand's website · 2026-10-04
Partnership and licensing models, including funded discovery, platform transfer, and non-exclusive programs for proprietary modules like TCE and heterodimer technologies.
Audience
Target industry Brand's website · 2026-10-04
Biopharmaceutical companies and partners seeking therapeutic protein discovery, optimization, and development.
Is this your business?
The information above is publicly sourced — assembled by Optimly from Adimab's website and public pages.
Claim this profile to publish your own verified Business Profile and speak for Adimab across the index.
Claim Adimab — free →Page last updated 2026-10-17.